We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • Stock information
    • Governance
    • Documentation

Press releases

25 January 2018

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

25 January 2018

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

10 January 2018

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

05 December 2017

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

06 November 2017

GenSight Biologics to Participate in Multiple Conferences in November

26 October 2017

GenSight Biologics Reports its Cash Position as of September 30, 2017

25 October 2017

GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

16 October 2017

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

04 October 2017

GenSight Biologics to Attend Chardan Gene Therapy Conference

02 October 2017

GenSight Biologics integrates the Enternext® PEA-PME 150 index

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • View next 9 articles

Stay informed

Subscribe to the newsletter to get the latest GenSight Biologics news

Fields marked with an * are required
© 2019 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page